105

140

FLUBIO HL

Package insert of Influenza Vaccine (Split Virion), Inactivated

[Drug Name]
Generic Name: Influenza Vaccine (Split Virion), Inactivated
English Name: Influenza Vaccine (Split Virion), Inactivated
Chinese Pinyin: Liugan Bingdu Liejie Yimiao

[Composition]
The vaccine is prepared from influenza virus type A and B prevalent strains recommended by WHO. The virus strains are propagated in embryonated chicken eggs. After incubation ,the virus suspensions in allantoic cavities are harvested. The vaccine is prepared by inactivation, concentration, purification and splitting. The vaccine is a slightly opalescent liquid.
Dosage form: suspension for injection
Active ingredients: Hemagglutinin of prevalent strains of influenza virus in current year. The vaccine 0.5 mL contains:
A/VICTORIA/4897/2022 (H1N1) PDM09 - LIKE VIRUS (A/VICTORIA/4897/2022, IVR-238) 15μg hemagglutinin
A/THAILAND/8/2022 (H3N2)-LIKE VIRUS (A/THAILAND/8/2022, IVR-237) 15μg hemagglutinin
B/AUSTRIA/1359417/2021- LIKE VIRUS (B/AUSTRIA/1359417/2021, BVR-26) 15μg hemagglutinin

Excipients:

Sodium Chloride	4250μg
Sodium Dihydrogen Phosphate	137μg
Disodium Hydrogen Phosphate	547μg

[Indication]
It is indicated for active immunization againts influenza disease caused by influenza virus subtypes A and type B contained in the vaccine for prophylaxis of the influenza caused by the contained vaccine strain. The vaccine is approved for use in vulnerable people and high risk population for influenza complication, such as children over 3 years of age, the elderly, the weak and people in influenza epidemic areas.

[Specifications]
This vaccine per single human dose is 0.5 mL in pre filled syringe containing not lower than 15μg HA for each virus strain.

[Posology]
Intramuscularly inject the vaccine in the region of the deltoid muscle of the upper arm. Persons 3 years of age and older should vaccinate with a single dose of 0.5 ml before or during the flu epidemic season.

[Adverse Reactions]
1.Pain, tenderness, redness, swelling, and pruritus at the injection site may appear in a few subjects within 24 hours post-vaccination. Normally it will disappear in two or three days.
2.A few subjects would have transient fever after vaccination, but it will disappear without treatment in a short period.
3.Rare adverse reactions include transient cold symptoms and general malaise may occur, but will vanish without special treatment.
4.Very rare adverse reactions include Anaphylactic shock, and Guillain-Barre Syndrome.

[Contraindications]
1.Subjects with allergic to eggs and other ingredients in the vaccine.
2.Subjects who have acute illness, severe chronic diseases, acute exacerbation of chronic disease and fever.
3.Subjects with a diagnosis of uncontrolled epilepsy or other nervous system progressive disease, and history of Guillain-Barre Syndrome.

[Precautions]
1.The vaccine should be used within the shelf life stated on the label.
2.Adrenaline should be available for first aid in case of severe anaphylactic reactions. The recipients shall take a rest for at least 30 minutes on site after vaccination.
3.Revaccination is prohibited if any neurological reaction occurs after vaccination.
4.Do not use the vaccine with the presence of any leakage of container or illegible label or turbid or any clumps not dispersed after shaking in the container.
5.Use immediately once the container is opened.
6.Intravenous injection of the vaccine is strictly contraindicated.
7.Immunocompromised subjects or those who have any questions before use should consult and comply with the medical advice.
8.Subjects treated with immunoglobulin shall defer for at least one month for the vaccination with this vaccine.
9.This vaccine should only be given to pregnant women on medical advice.

[Drug Interactions]
There is no data on administration Flubio HL simultaneously with another vaccine
Immunosuppressive therapies may influence the immune response to influenza.

[Pharmaceutical properties]
Pharmacodynamics properties
To evaluate the immunogenicity, clinical trials of the phase III and phase IV were carried out respectively before and after market authorization. Three indicators including HI antibody positive conversion rate, the proportion of HI antibody protective level and the average fold increase of antibody after vaccination were assessed. Table 1 provides a summary of the immunogenicity data.

Table 1 Immunogenicity data from clinical trials

Clinical phase	Year/ virus strain	Subject(s) and age group	Type	HI antibody positive conversion rate (%)	HI antibody protective level (%)	Average fold increase of antibody
III	2005-2006	500 (above 6 months)	H1N1	81.6	97.4	11.0
			H3N2	92.4	98.6	21.1
			B	78.0	95.6	7.3
IV	2011-2012	500 (above 3 years)	H1N1	79.3	89.3	17.8
			H3N2	82.8	98.3	15.2
			B	67.6	93.0	6.3

Clinical studies
To evaluate the safety of the vaccine, clinical trials of the phase III and phase IV were carried out respectively before and after market authorization. Table 2 provides a summary of the local and systemic adverse reaction experience.

Table 2: Safety data from clinical trials

Type of adverse reaction	Clinical phase III	Clinical phase IV
	2005-2006*	2011-2012*
	N=558	N=3083
	above 6 months	above 3 years
Local adverse reactions		
Red & swelling	31 (5.56%)	12(0.39%)
Induration	1(0.18%)	20(0.65%)
Pain	-	8(0.26%)
Pruritus	-	3(0.10%)
Other	16(2.87%)	-
Systemic adverse reactions		
Fever	15(2.69%)	126(3.32%)
Cough	-	3(0.10%)
Headache	-	8(0.26%)
Dizziness	-	6(0.19%)
Nausea	-	5(0.16%
Fatigue	-	3(0.10%)
Limbs ache	-	3(0.10%)
Rhinorrhea	-	3(0.10%)
Rhinobyon	-	2(0.06%)
Diarrhea	-	1(0.03%)
Tinnitus	-	1(0.03%)
Vomit	-	1(0.03%)
Rash	-	1(0.03%)
Chest congestion	-	1(0.03%)

工艺路线：印刷

纸张：70g双胶

Black 301 144 尺寸 切线

环球印務 GLOBAL PRINTING

ARTWORK 报告单 / REPORT

www.globalprinting.cn

产品编码 SMSW000069-1
工艺组长 苗行
尺寸(mm) 105×140mm
刀版编号 刀版编号
销售负责 毛佳睿
工 艺 员 吴蔷薇
平面工程师 时晓育
输出日期 20240401 17:10:22
文件名称 SMSW000069_1_z_V1

顾客名称 华兰生物疫苗股份有限公司
产品名称 流感病毒裂解疫苗15ug（0.5ml）注射器1支（成人）印尼版说明书

请您在确认稿件内容无误后签字确认

□颜色 □文字 □版式 □成品尺寸 □条形码

顾客签字/日期：

No. 01

此文件为确认定稿使用，为避免系统差异造成的电子文件异常，请勿修改文件，需修改请联系我司告知我司修改内容，我司修改后重新确认定稿。

105

140

Rapid heartbeat	-	1(0.03%)
Other	4(0.72%)	-

*The year of the virus strains

Pharmacokinetic properties

Evaluation of pharmacokinetic properties is not required for vaccines.

Preclinical safety data

1. Allergy test

In order to investigate whether substances leading to allergy of human exist in Influenza Vaccine (Split Virion), Inactivated, we carried out animal allergy test for sample manufactured for test and TritonX-100 splitting agent with various concentration.

Vaccinated guinea pigs of 300~400g with samples subcutaneously and vaccinated 3 guinea pigs with each sample. Each one was vaccinated with 1 ml. After 1 week, vaccinated guinea pigs in the same way to cause sensitization to them. 3 weeks after the 2nd vaccination, vaccinated each guinea pig with the same sample of 0.5ml, while vaccinated 3 guinea pigs with human albumin and physiological sodium chloride solution in the same way as positive control and negative control respectively. Observed whether allergy occurred to guinea pigs in test group.

Through observing result within 3 days after vaccination, positive control and negative control were established and there was no guinea pig dying nor rhinocnesmus, sneezing, restlessness, dyspnea, shock, spasm and other allergy symptoms occurred to test group(including vaccine group and group of TritonX-100 splitting agent with various content). Test result showed that the vaccine and TritonX-100 splitting agent used for it would not cause sensitization to guinea pigs.

2. Abnormal toxicity test

In order to validate product safety further, we sampled samples manufactured for test and inspected whether potential abnormal toxicity exists in the product as per Abnormal Toxicity Test Procedure in the Chinese Biological Product Procedure(2010 version). By carrying out abnormal toxicity test for mice and guinea pig, the test result was in line with requirements of the procedure, thus proved Influenza Vaccine (Split Virion), Inactivated was safe.

3. Acute toxicity test

In order to validate safety of TritonX-100 splitting agent used in the production of Influenza Vaccine (Split Virion), Inactivated further, we carried out acute toxicity test with samples manufactured for test and TritonX-100 splitting agent with various concentration. Vaccinated 5 mice of 14~16g with TritonX-100 splitting agent with each concentration intraperitoneally. Vaccinated each one with 0.5ml and observed survival rate and weight of mice after 1 week since vaccination. Test result showed that 5 mice of each test group were alive and gained weight. From the acute toxicity test, Triton X-100 with certain concentration was proved to be safe to animals.

Through pertinent literatures, reports, the current situation that Triton X – 100 is allowed to be used in the production of some products at home and abroad, as well as the test results above, all of them show that the usage amount and residual amount of Triton X – 100 in vaccine are safe to animals.

[Storage]

Store and ship at 2-8°C, protected from light. Do not freeze.

[Packaging]

Prefilled syringe, packaged with bromobutyl rubber stopper.

DUS, 1 PREFILLED SYRINGE @ 0,5 ML (1 DOSIS)

[Shelf Life]

12 months.

[Reg. No.]

Prefilled syringe 0.5 mL: DKI2055500143B1

[Manufactured by]

Hualan Biological Bacterin Inc.
Jia No.1-1, Hualan Ave., Xinxiang, Henan, China
Tel: 86-373-3519992
Fax: 86-373-3519991
Post Code: 453003
Website: http://www.hualanbio.com

[Imported by]

PT Bio Farma (Persero)
Jalan Pasteur no. 28, Bandung, Indonesia
Tel: (+62 22) 2033755
Fax: (+62 22) 2041306
Post Code: 40161

HARUS DENGAN RESEP DOKTER

Informasi Produk untuk Pasien

Nama Obat

Flubio HL

Bentuk sediaan

Suspensi Injeksi

Pemerian Obat

Cairan agak putih-susu yang bebas dari partikel asing.

Komposisi zat aktif

Hemagglutinin dari jenis virus influenza yang umum pada tahun ini.

Setiap dosis (0.5 mL) mengandung:

A/VICTORIA/4897/2022 (H1N1) PDM09 - LIKE VIRUS (A/VICTORIA/4897/2022, IVR-238) 15µg hemagglutinin

A/THAILAND/8/2022 (H3N2)-LIKE VIRUS (A/THAILAND/8/2022, IVR-237) 15µg hemagglutinin

B/AUSTRIA/1359417/2021- LIKE VIRUS (B/AUSTRIA/1359417/2021, BVR-26) 15µg hemagglutinin

Kekuatan Obat

Vaksin ini per dosis tunggal manusia adalah 0,5 ml dalam *pre filled syringe* yang mengandung tidak kurang dari 15 µg HA untuk setiap jenis virus.

Indikasi

Flubio HL digunakan untuk pencegahan terhadap influenza yang disebabkan virus influenza yang terkandung pada vaksin. Vaksin ini digunakan pada orang yang rentan dan risiko tinggi, misalnya anak anak diatas 3 tahun, lanjut usia, lemah, dan orang yang berada pada daerah epidemic influenza.

Posologi dan cara pemberian

1.Individu berusia 3 tahun ke atas divaksinasi dengan dosis tunggal 0,5 mL.
2.Injeksikan vaksin secara intamuskular di daerah otot deltoid lengan atas.

Kontraindikasi

1.Individu yang alergi telur dan bahan bahan lain dalam vaksin.
2.Individu yang memiliki penyakit akut, penyakit kronis berat, eksaserbasi akut penyakit kronis, dan demam.
3.Individu dengan diagnosis epilepsi yang tidak terkontrol atau penyakit progresif sistem saraf lainnya, dan riwayat Sindrom Guillain-Barre.

Peringatan dan perhatian

1.Vaksin harus digunakan dalam usia simpan yang tercantum pada label.
2.Adrenalin harus tersedia untuk pertolongan pertama jika terjadi reaksi anafilaksis yang parah. Penerima harus beristirahat setidaknya 30 menit di lokasi setelah vaksinasi.
3.Vaksinasi ulang dilarang, jika ada reaksi neurologis yang terjadi setelah vaksinasi.
4.Vaksin tidak boleh digunakan apabila terdapat kebocoran wadah atau label yang tidak terbaca atau terdapat gumpalan yang tidak hilang setelah diguncang dalam wadah.
5.Gunakan segera setelah wadah dibuka.
6.Injeksi vaksin secara intravena sangat dilarang.
7.Individu yang diobati dengan imunoglobulin harus menunda setidaknya satu bulan untuk vaksinasi dengan vaksin ini.
8.Individu immunocompromised atau mereka yang memiliki pertanyaan sebelum mengguakan vaksin, harus berkonsultasi dan mematuhi saran medis.
9.Konsultasikan terlebih dahulu ke dokter untuk pemberian kepada wanita hamil.

Interaksi Obat

Tidak ada data terkait pemberian Flubio HL bersama dengan vaksin lain.

Efek samping

1.Nyeri, nyeri tekan, kemerahan, pembengkakan, dan pruritus di tempat suntikan dapat muncul pada beberapa individu dalam 24 jam setelah vaksinasi. Biasanya reaksi tersebut akan hilang dalam dua atau tiga hari.
2.Beberapa individu akan mengalami demam sementara setelah vaksinasi, tetapi akan hilang tanpa pengobatan dalam waktu singkat.
3.Efek samping yang jarang terjadi antara lain gejala flu sementara dan malaise umum dapat terjadi, tetapi akan hilang tanpa perawatan khusus.
4.Reaksi yang sangat jarang terjadi antara lain Syok anafilaksis, dan Sindrom Guillain-Barre.

Cara penyimpanan

Simpan dan kirim pada 2-8°C, terlindung dari cahaya. Jangan dibekukan.

Nomor Izin Edar

DUS, 1 PREFILLED SYRINGE @ 0,5 ML (1 DOSIS)
Reg No. : DKI2055500143B1

Diproduksi oleh

HUALAN BIOLOGICAL BACTERIN INC.
Jia No.1-1, Hualan Ave., Xinxiang, Henan, China
Tel: 86-373-3519992
Fax: 86-373-3519991
Post Code: 453003

Diimpor oleh

PT Bio Farma (Persero)
Jalan Pasteur no. 28, Bandung, Indonesia
Tel: (+62 22) 2033755
Fax: (+62 22) 2041306
Post Code: 40161

Harus dengan resep dokter

工艺路线：印刷

纸张：70g双胶

Black 185 144 301 尺寸 切线

环球印務 GLOBAL PRINTING
ARTWORK
报告单 / REPORT
www.globalprinting.cn

产品编码 SMSW000069-4
工艺组长 苗行
尺寸(mm) 105×140mm
刀版编号 刀版编号
销售负责 毛佳睿
工艺员 吴蔷薇
平面工程师 时晓育
输出日期 20240401 17:10:28
文件名称 SMSW000069_1_b_V1

顾客名称 华兰生物疫苗股份有限公司
产品名称 流感病毒裂解疫苗15ug（0.5ml）注射器1支（成人）印尼版说明书

请您在确认稿件内容无误后签字确认

□颜色 □文字 □版式 □成品尺寸 □条形码

顾客签字/日期：

No. 01

此文件为确认定稿使用，为避免系统差异造成的电子文件异常，请勿修改文件，需修改请联系我司告知我司修改内容，我司修改后重新确认定稿。